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1. Introduction 
Incorporation studies with 13C-acetates and 13C- 
propionates led to the proposal of a biogenetic scheme 
for rifamycin S [ 1 ] , in which a single polyketide chain 
is initiated by a seven carbon amino unit of unknown 
metabolic origin (fig. 1). Such a scheme appeared 
applicable to ansamycin biogenesis in general and sug- 
gested that all naphthalenic ansamycins could derive 
from a common progenitor. Its validity has now been 
demonstrated by the isolation of rifamycin W [2], an 
intermediate in rifamycin S biosynthesis, which struc- 
turally [3] resembles the streptovaricins and thus 
represents the missing link in naphthalenic ansamycin 
biogenesis. Further evidence has come from studies on 
the incorporation of [ 1 -l 3 C] propionate into strepto- 
varicin D [4] and geldanamycin [S] . 
Seven carbon 
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Fig. 1. Biogenetic scheme for rifamycin S (modified from 
ref. [6]). 
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Studies on the origin of the seven carbon unit are 
of interest due to the unusual meta amino substitu- 
tion of a benzoic acid and because of the lack of shiki- 
mate incorporation into this aromatic moiety [6]. 
We have reported [6] that the only precursors to 
specifically label the rifamycin chromophore are 
[3,4-‘4C]glucose and [1-‘4C]glycerate. In addition, 
the pattern of [ 1 -I3 C] glucose incorporation into the 
quinone ring and C-8 [6] recalled that obtained by 
Davis et al. [7] in shikimate with [l-14C]glucose, 
suggesting an analogous origin for this moiety. How- 
ever, the low level of incorporation and partial overlap 
of certain signals on the CMR spectrum precluded a 
definitive interpretation of these results. 
2. Materials and methods 
2.1. Preparation and incorporation of l3 C enriched 
precursors 
Sodium [ 1 -l 3 Clglycerate (90% enriched) was 
prepared from Na ’ 3CN and glycolaldehyde by the 
method of Ashworth [8] and added to a fermentation, 
48 hr after inoculation, to give a final concentration of 
5 mg/ml. [l-l “C] glucose (15% enriched) was added to 
a fermentation at zero time to give a final concentration 
of 120 mg/ml. Nocardia mediterranei was cultured in 
a complex organic medium for a total of 168 hr and 
the [13C]enriched rifamycin B formed was then extrac’ 
ed and transformed into rifamycin S as previously 
described [l] . ’ 3 C enriched compounds were purchase’ 
from Merck Sharp and Dohme of Montreal, Canada. 
2.2. Recording of 1 3 C spectra 
Proton-decoupled Fourier transform carbon mag 
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netic resonance (CMR) spectra were recorded at 25.2 
MHz on a Varian XL-100 spectrometer in dimethyl 
sulphoxide-d6 (DMSO-de) solution with dissolved 
tetramethylsilane (TMS) as reference and using inter- 
nal deuterium lock. Spectra 2A and 2B: 46 mg samples 
of rifamycin S were dissolved in 0.5 ml of DMSO-de 
in a 5 mm tube; 10 000 scans were accumulated with 
an acquisition time of 0.7 set and processed by a 
Digilab 32K core computer. Spectra 2C and 2D: 46 
mg samples of rifamycin S were dissolved in 2 ml of 
DMSO-d6 in a 12 mm tube; 70 000 scans were accumul- 
ated with an acquisition time of 0.7 set and processed 
with a Varian 620 L computer. 
3. Results and discussion 
We now report a considerably improved incorpora- 
tion of [ 1 -r 3 C] glucose into rifamycin S than obtained 
earlier [6] and, by recording the CMR spectrum in 
B 
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DMSO-de instead of CDC13, have obtained a better 
separation of the signals concerned. Assignment of the 
resonances was performed using the techniques pre- 
viously described [9]. Fig. 2 shows the low-field region 
CMR spectrum of rifamycin S at natural abundance 
(A) and of rifamycin S biosynthetically enriched with 
[ 1 -l 3 C] glucose (B). Of the seven relevant carbons 
only two are enriched: C-l and C-10; the relative en- 
richment factors for these carbons, calculated from 
the ratio of intensities on the enriched and natural 
abundance spectra, are 3.4 and 1.9, respectively. 
Further evidence on the metabolic origin of this unit 
has come from studying the incorporation of [l-13C]- 
glycerate. The CMR spectrum of rifamycin S biosyn- 
thetically enriched with this precursor is shown in fig. 
2D (since instrumental conditions were different for 
D 
‘ I 1 I 1 I I I 
I I 
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Fig. 2. Downfield region of the proton-decoupled FT CMR spectra of rifamycin S recorded at 25.2 MHz in DMSOd, . A and C, 
natural abundance; B, biosynthetically enriched with [l- ‘aC]glucose; D, biosynthetically enriched with [I-’ 3C]glycerate. Chemical 
shifts are in ppm from internal TMS. Enriched carbons on spectra B and D are numbered; NB. Only signals belonging to the seven 
carbon unit (heavy line on the formula of rifamycin S) have been considered. 
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Fig. 3. Suggested metabolic scheme explaining the pattern of 
labelling obtained in the seven carbon unit with [l-’ 'Cl- 
glycerate and [l-l 'Clglucose as precursors. 
the two enriched samples a second natural abundance 
spectrum, 2C, is included as control for 2D). Also in 
this case there are only two carbons enriched: C-3 
and C-8, with relative enrichment factors of 2.0 and 
4.4, respectively. We interpret these data as evidence 
for a shikimate-type origin of this moiety. However, 
experiments with 14C-shikimate [6] have shown a 
very poor, non-specific incorporation of this precursor 
into rifamycin S. This apparent contradiction would 
be accounted for if the seven carbon unit derived 
from an intermediate of aromatic biosynthesis before 
the level of shikimate, i.e. 5dehydroquinate or S-dehy- 
droshikimate. A metabolic scheme explaining the 
observed pattern of labelling is proposed in fig. 3. In 
analogy with the established incorporation of [ 1-14C]- 
glucose into shikimate [7], the higher enrichment at 
C-l of rifamycin S with [ 1 -r3 Clglucose is taken to 
indicate that it derives from the methylene carbon of 
phosphoenol pyruvate rather than C-4 of tetrose phos- 
phate. Similarly, the higher enrichment at C-8 with 
[ 1-l 3 C] glycerate suggests that it derives from the car- 
boxy1 of phosphoenol pyruvate. This establishes the 
orientation of the seven carbon unit placing the double 
Fig. 4. Proposed mechanism of ring closure to give the naph- 
thalenic chromophore. 
bond of _5-dehydroshikimate and shikimate between 
C-9 and C-10. This in turn would favour ring closure 
between C-5 and C-10 by Michael addition giving rise 
to the naphthoquinone chromophore in a manner 
analogous to the menaquinones [lo] (see fig. 4) with 
the C-8 carboxyl having initiated polyketide chain 
growth. Classical studies on the origin of the carbon 
skeleton of shikimate [7] have shown that [3,4-14C]- 
glucose labels C-3 and C-4 (equivalent to C-2 and C-3 
of rifamycin) via the intermediate formation of 
[ 1,2-l 4 C] erytErose-4-phosphate. Assuming a shikimate 
type origin, the absence of label at C-3 of rifamycin 
indicates that no [3,4-13C] glucose-6-phosphate was 
formed by 7 everse glycolysis from [ 1 -l 3 C] glycerate. 
However, iabel from this precursor must arrive at 3- 
phosphoglyceraldehyde to form [2-l 3 C] erythrose4- 
phosphate, thus selectively enriching C-3 of rifamycin. 
Similar seven carbon meta amino moieties are evident 
in the other ansamycins [2,3] and also in mitomycin 
C, and a common biosynthetic origin has been suggest- 
ed [ 1 I] . Data on the biosynthetic origin of this unit 
in mitomycin C are insufficient to allow definite con- 
clusions, but it is difficult to reconcile the reported 
[ 121 specific incorporation of [ 1 -14 C] glucose into 
the methyl carbon on the benzoquinone ring with a 
shikimate-type origin, as this position should derive 
from C-3 and C-4 of the labelled hexose. 
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